While large volumes of real-world data (RWD) are now available, pharmaceutical R&D and market access teams often struggle with aligning analytical methods, data sources, and compliance expectations across different jurisdictions. This disconnect can slow clinical development timelines and affect the efficiency of evidence generation programs. To address this gap, MEDDDICAL has launched an advisory service focused on helping organizations structure and apply real-world data strategies more effectively across clinical development and market access workflows.
More details can be found at https://medddical.com/
The increasing reliance on RWD and RWE reflects a broader shift in how healthcare evidence is evaluated globally. According to the UC Berkeley School of Public Health, more effective use of real-world data may support faster and more efficient clinical trials, particularly when integrated with traditional study designs. At the same time, regulatory agencies are formalizing pathways for its use.
The U.S. Food and Drug Administration (FDA) issued updated draft guidance in 2024 for drugs and biologics, followed by 2025 guidance for medical devices, recognizing electronic health records and claims data as valid scientific evidence when appropriately analyzed. In Europe and the UK, the European Medicines Agency’s DARWIN EU initiative and the National Institute for Health and Care Excellence (NICE) have similarly expanded frameworks for incorporating RWE into regulatory and reimbursement decisions.
Despite this progress, pharmaceutical organizations continue to face fragmentation across global regulatory systems, with differing standards for data quality, methodology, and acceptance criteria. This complexity can lead to inefficiencies when companies engage multiple data vendors without clearly defined analytical and regulatory requirements, increasing the risk of misaligned study design and delayed submissions.
Within this context, new advisory models focused on early-stage strategy and requirements definition are being used in response to these structural challenges in the RWE ecosystem. MEDDDICAL's approach centers on supporting organizations in clarifying their evidence-generation needs prior to vendor selection, with the aim of reducing iteration cycles in study design and improving alignment with regulatory expectations.
More broadly, the growing use of real-world data in regulatory and reimbursement decision-making is reshaping how evidence is planned and evaluated in drug development. As datasets become more diverse and global regulatory expectations remain inconsistent, greater emphasis is being placed on early decisions around study design, data suitability, and methodological standards to reduce downstream inefficiencies.
About MEDDDICAL
MEDDDICAL is an independent advisory focused on real-world evidence (RWE) strategy for life sciences organizations. The consultancy supports pharmaceutical and MedTech teams in evaluating data requirements, study design considerations, and regulatory alignment needs across clinical development and market access programs.
Additional information is available at https://medddical.com
MEDDDICAL
Aptos 221
Edificio D2C
Sotogrande
Cadiz
11310
Spain